TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15585624
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) based immunotherapy
Study: 11322841
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (individualized stress management)
Study: 11322841
Drug: Combined sample
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sample (after treatment for wait list control)
Study: 9032045
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (80 parts per million)
Study: 8302530
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of lovastatin
Study: 3558996
Drug: Azatadine (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azatadine (topical tricyclic antihistamine)
Study: 27602906
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 120 mg/kg over 1 hour
Study: 21495269
Drug: Adalat 10
Normalized name: Adalat 10mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalat 10 capsule
Study: 22850606
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg orally after radiotracer injection
Study: 19960970
Drug: Ginsenosides (GS)
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenosides (GS) Capsule (50 mg) twice daily
Study: 19960970
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule of equal dosage
Study: 11585356
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of retinyl palmitate
Study: 11585356
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of retinyl palmitate plus 2 microg of 1,25(OH)2D3
Study: 9572322
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 microg four times daily
Study: 7837406
Drug: DFK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFK group (total intravenous anesthesia with droperidol, fentanyl and ketamine)
Study: 27018027
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Ibuprofen + amoxicillin, clavulanic acid)
Study: 27018027
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (Ibuprofen only)
Study: 20575711
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy suspension for 1 or 2 months before the next screening mammogram.
Study: 19106467
Drug: Gradia (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradia (G)
Study: 8637789
Drug: Biweekly schedule
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly schedule of 1.2 million U intramuscular benzathine penicillin G (BPG)
Study: 8637789
Drug: 4-week schedule
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week schedule of 1.2 million U intramuscular benzathine penicillin G (BPG)
Study: 31125274
Drug: Brigatinib treatment
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brigatinib treatment
Study: 16272960
Drug: GW320659 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW320659 (15 mg/day)
Study: 10197321
Drug: Coumarin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin 90 mg/day (Group A)
Study: 10197321
Drug: Coumarin 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin 135 mg/day (Group B)
Study: 8657434
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 60 mg/ml
Study: 8657434
Drug: Indomethacin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 4.5 mg/ml
Study: 8657434
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (SA) 60 mg/ml
Study: 2182235
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (Eminase)
Study: 2182235
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (Eminase) and Intracoronary streptokinase
Study: 114042
Drug: Low-lactose milk
Normalized name: CASEINATE/DEXTROSE/LACTOSE/MILK/MINERALS/MULTIVITAMINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose milk (500 ml twice daily for 1 month)
Study: 25556539
Drug: Ropivacaine 0.75%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75%, 20 mL
Study: 25556539
Drug: 0.9% saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline, 20 mL
Study: 24144222
Drug: Nebulised magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised magnesium sulphate (MgSO4) 151 mg
Study: 1746414
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (placebo)
Study: 3459390
Drug: Imipenem coadministered
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem coadministered with cilastatin (1 g of imipenem and equal amounts of cilastatin)
Study: 3459390
Drug: Moxalactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (2 g)
Study: 26244417
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) as an adjunct to Light Therapy (LT) for four weeks after two weeks of LT.
Study: 26244417
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (NT) after two weeks of Light Therapy (LT).
Study: 22525670
Drug: Noninvasive cortical
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive cortical stimulation therapy
Study: 10079411
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (0.6 mg/mL)
Study: 2184134
Drug: Thymopentin (TP-5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP-5) at 50 mg s.c. three times per week for one month
Study: 28295825
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (n=50), three sessions (once/week) including desensitization manoeuvres of the central nervous system
Study: 11508581
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) in combination with low dose corticosteroids after 12 months of therapy
Study: 7826827
Drug: Bendrofluazide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (10 mg)
Study: 29308927
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CRMRF
Study: 29308927
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CRMRF
Study: 29308927
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose PSWT
Study: 10596458
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of insulin (0.1 U/kg)
Study: 10596458
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of insulin (0.05 U/kg)
Study: 1913493
Drug: DDP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP with DSM (600 mg degradable starch microspheres)
Study: 1913493
Drug: DDP alone
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP alone (25 mg/m2)
Study: 31313548
Drug: Triple pill
Normalized name: Triple Wormer Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple pill of telmisartan/amlodipine/hydrochlorothiazide
Study: 31313548
Drug: Dual combination
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combination of telmisartan/hydrochlorothiazide
Study: 24129543
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (Coping Cat)
Study: 24129543
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive‐behavioral therapy and medication
Study: 17324657
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention (nutrition counseling following the ADA medical nutrition therapy protocol)
Study: 15014864
Drug: Hypromellose and
Normalized name: Hypromellose and phenylephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypromellose and Lacri‐Lube combination (HL)
Study: 9659017
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg.kg‐1
Study: 8595681
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine 2% (1 ml NaHCO3 per 10 ml of solution) injected immediately
Study: 8595681
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine 2% (1 ml NaHCO3 per 10 ml of solution) injected one hour after preparation
Study: 2668006
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine at a dose of 100 mg kg‐1 b.w. every 12 h for 36 h
Study: 31187437
Drug: 300-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg single-dose tafenoquine
Study: 28437278
Drug: Landiolol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (12 mg/mL formulation) administered via dose-escalation regimen (10 μg/kg BW/min for 2 hours, 20 μg/kg BW/min for 2 hours, 40 μg/kg BW/min for 20 hours, 6 hours follow-up)
Study: 28437278
Drug: Landiolol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (12 mg/mL formulation)
Study: 16818564
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of folate (60 microg/kg per day)
Study: 9390112
Drug: Montelukast 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 0.4 mg
Study: 2862946
Drug: Temazepam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (40 mg)
Study: 27127136
Drug: Acetium lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetium lozenge (slow-release L-Cysteine)
Study: 25029426
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (0.7 μg/kg/h for 12.5 h)
Study: 18363032
Drug: Monascus purpureus
Normalized name: Monascus purpureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monascus purpureus Went rice (600 mg twice per day for one month, then once daily)
Study: 18363032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antidyslipidemic therapy)
Study: 15601270
Drug: Intravenous colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous colloid (n = 18)
Study: 12381337
Drug: Orlistat given
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat given as a capsule with the meal
Study: 11247198
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid containing multivitamin preparation (4 mg of folic acid, calcium, iron, zinc, vitamins A, B1, B2, B6, C, D, and nicotinamide)
Study: 9105061
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FP and SLM
Study: 8456421
Drug: sulotroban (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulotroban (2 mg/min, 4 mg/min, 8 mg/min)
Study: 3104991
Drug: Enprostil (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (70 micrograms oral dose)
Study: 3104991
Drug: Enprostil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (10 micrograms/ml) in rats
Study: 22471135
Drug: Ergotamine and
Normalized name: Belladonna alkaloid and ergotamine and phenobarbital only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine and Caffeine tablets (oral administration)
Study: 20937992
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m² on day 1 and topotecan 0.75 mg/m² on days 1-5 followed by paclitaxel 175 mg/m² on day 1 and carboplatin (AUC = 5) on day 1 for four cycles, then four cycles of paclitaxel and carboplatin.
Study: 18260172
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate (2 mg every 2 months)
Study: 18260172
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate (3 mg every 3 months)
Study: 18260172
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral ibandronate (2.5 mg)
Study: 12798874
Drug: Chemical removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical removal of zona pellucida by using acidic Tyrode's solution
Study: 10653210
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg sustained-release twice daily + 5 mg immediate-release with morning dose)
Study: 10653210
Drug: Methylphenidate (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (15, 30, and 60 mg immediate-release in ascending doses)
Study: 23011728
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (50 mg)
Study: 23011728
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (150 mg)
Study: 23011728
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (500 mg)
Study: 15639293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (100 microg/week pegylated interferon alfa-2b and 100 mg/day lamivudine)
Study: 15639293
Drug: Monotherapy (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (100 microg/week pegylated interferon alfa-2b and placebo)
Study: 16640105
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy and monotherapy
Study: 31849035
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral hyoscine twice daily for 1 week, followed by once daily for 1 week
Study: 24881286
Drug: Crotamiton 10%
Normalized name: CROTAMITON 10% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crotamiton 10% cream
Study: 19025972
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan at a dose of 1.2 mg/m2 twice daily for 5 days (Arm A)
Study: 19025972
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan once daily for 10 days (Arm B)
Study: 29396094
Drug: Treatment-related deaths
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related deaths
Study: 15196585
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (0.25, 0.5, 1, 2.5, 5, or 10 mg) administered via 10 min i.v. infusion
Study: 9018183
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (500 micrograms/dose) with the first and third dose of albuterol
Study: 8359791
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) for 2 years
Study: 25634521
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid at C3 dose
Study: 22990631
Drug: Gastric lavage
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric lavage with 10 ml/kg of normal saline
Study: 11940070
Drug: Rofecoxib (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (cumulative dose of 25 mg administered in doses of 6.25 mg, 6.25 mg, and 12.5 mg)
Study: 10080652
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol (Painlax and Tramal)
Study: 7583525
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) replacement therapy for 6 months
Study: 2076716
Drug: Liposomal preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal preparation of beta‐methasone dipropionate (0.039%)
Study: 2076716
Drug: Commercial propylene
Normalized name: propylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial propylene glycol-gel containing 0.064% beta‐methasone dipropionate
Study: 7042366
Drug: Indoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (200 mg q.i.d.)
Study: 7042366
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg q.i.d.)
Study: 31887169
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin spray (800 μg, 2 puffs)
Study: 28629180
Drug: Sausages enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sausages enriched with approximately 250 mg EPA and DHA per 80 g daily for 8 weeks (n = 22)
Study: 20728875
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg twice daily DMXB-A
Study: 20728875
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg twice daily DMXB-A
Study: 12626975
Drug: Low-dose LY315920Na/S-5920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose LY315920Na/S-5920 (target plasma concentration of 200 ng/mL, n = 196)
Study: 12626975
Drug: High-dose LY315920Na/S-5920
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose LY315920Na/S-5920 (target plasma concentration of 800 ng/mL, n = 194)
Study: 12626975
Drug: Low-dose LY315920Na/S-5920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose LY315920Na/S-5920 (n = 51)
Study: 12626975
Drug: High-dose LY315920Na/S-5920
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose LY315920Na/S-5920 (n = 48)
Study: 11735710
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene cream
Study: 11735710
Drug: 0.05% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tazarotene cream
Study: 11735710
Drug: 0.025% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tazarotene cream
Study: 11735710
Drug: 0.01% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% tazarotene cream
Study: 27353466
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g, three times daily for 7 days
Study: 17970818
Drug: proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: proposed treatment method
Study: 16436240
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (assertive community treatment with family involvement and social skills training)
Study: 10787430
Drug: margarine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: margarine with phytosterol esters (MSE) (1.84 g/d)
Study: 10787430
Drug: margarine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: margarine with phytostanol esters (MSA) (1.84 g/d)
Study: 1699400
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic agents (flecainide and encainide)
Study: 1699400
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III antiarrhythmic agents (amiodarone)
Study: 342629
Drug: Whole-virus vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccine (50 CCA units)
Study: 342629
Drug: Whole-virus vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccine (two inoculations)
Study: 335000
Drug: Split-product vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-product vaccine
Study: 30952216
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (CTRL)
Study: 28198465
Drug: Norepinephrine-dopamine reuptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine-dopamine reuptake inhibitor (bupropion)
Study: 21802026
Drug: ICX72 (Capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICX72 (Capsaicin nasal spray)
Study: 18708287
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day arginine (ARG trial)